New classification for identifying HR myeloma based on cytogenetic abnormalities
Dr Zips discusses the use of advanced biological imaging technology to learn more about the biology of cancer and adapt the treatment approach accordingly. He talks about studies that have been done to learn about the relationship between the extent of hypoxia in animal tumours and how they respond to radiation, and how that can be incorporated into a fractionated treatment for humans. He explains how biological imaging might help us to assign patients to very individualized specific treatment and so improve outcome. He concludes with the statement that molecular imaging provides a great opportunity for a partnership between radiation oncologists and biological images to target cancer resistance.
New classification for identifying HR myeloma based on cytogenetic abnormalities
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Cancer mutation prediction using artificial intelligence
Best practice in HRRm testing in patients with metastatic prostate cancer
Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA
Choosing Wisely in radiology Tanzania